CCL22 and cancer: Apart from mediating the recruitment of antitumor T cell subsets, lncRNA could orchestrate the crosstalk between cancer cells and immune cells via the release of cancer-derived chemokines such as CC-chemokine ligand 2 (CCL2), vascular endothelial growth factor A (VEGFA), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), CCL5, CCL7, and CCL22 to enhance immunosuppressive lymphocyte recruitment and infiltration such as TAMs, MDSCs, and Tregs (27, 34).